AR113835A1 - Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía - Google Patents
Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugíaInfo
- Publication number
- AR113835A1 AR113835A1 ARP180103232A ARP180103232A AR113835A1 AR 113835 A1 AR113835 A1 AR 113835A1 AR P180103232 A ARP180103232 A AR P180103232A AR P180103232 A ARP180103232 A AR P180103232A AR 113835 A1 AR113835 A1 AR 113835A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- small intestine
- during
- peptibodies
- analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582055P | 2017-11-06 | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113835A1 true AR113835A1 (es) | 2020-06-17 |
Family
ID=66332372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103232A AR113835A1 (es) | 2017-11-06 | 2018-11-06 | Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11660328B2 (https=) |
| EP (1) | EP3706774A4 (https=) |
| JP (2) | JP7296958B2 (https=) |
| KR (1) | KR102825098B1 (https=) |
| CN (1) | CN111629745A (https=) |
| AR (1) | AR113835A1 (https=) |
| AU (1) | AU2018360744A1 (https=) |
| BR (1) | BR112020008936A2 (https=) |
| CA (1) | CA3079523A1 (https=) |
| IL (1) | IL274098B2 (https=) |
| MX (1) | MX2020004620A (https=) |
| TW (1) | TWI911137B (https=) |
| WO (1) | WO2019090209A1 (https=) |
| ZA (1) | ZA202002080B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020003736A2 (pt) * | 2017-08-22 | 2020-09-08 | Shire-Nps Pharmaceuticals, Inc. | polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| US20230129788A1 (en) * | 2020-03-30 | 2023-04-27 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| WO2021263040A1 (en) * | 2020-06-26 | 2021-12-30 | Shire-Nps Pharmaceuticals, Inc. | Stable peptibody formulations |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809318B1 (en) | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| JP2009510999A (ja) | 2005-07-29 | 2009-03-19 | エーエムプロテイン コーポレイション | キメラ治療剤 |
| EA200801174A1 (ru) * | 2005-10-24 | 2009-02-27 | Сентокор, Инк. | Антитела-миметики glp-2, полипептиды, композиции, способы и применения |
| JP5290177B2 (ja) | 2006-08-31 | 2013-09-18 | セントカー・インコーポレーテツド | Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途 |
| JP2008247789A (ja) | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | クローン病に伴う腸管狭窄の進展抑制用医薬組成物 |
| JP6206972B2 (ja) | 2011-09-12 | 2017-10-04 | アムニクス オペレーティング インコーポレイテッド | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
| UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN104540850B (zh) | 2012-05-03 | 2018-05-18 | 西兰制药公司 | 胰高血糖素样肽2(glp-2)类似物 |
| EP3082847A1 (en) * | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-11-05 WO PCT/US2018/059175 patent/WO2019090209A1/en not_active Ceased
- 2018-11-05 CN CN201880071791.3A patent/CN111629745A/zh active Pending
- 2018-11-05 EP EP18872377.9A patent/EP3706774A4/en active Pending
- 2018-11-05 CA CA3079523A patent/CA3079523A1/en active Pending
- 2018-11-05 JP JP2020526107A patent/JP7296958B2/ja active Active
- 2018-11-05 AU AU2018360744A patent/AU2018360744A1/en not_active Abandoned
- 2018-11-05 US US16/761,606 patent/US11660328B2/en active Active
- 2018-11-05 KR KR1020207013387A patent/KR102825098B1/ko active Active
- 2018-11-05 BR BR112020008936-2A patent/BR112020008936A2/pt unknown
- 2018-11-05 IL IL274098A patent/IL274098B2/en unknown
- 2018-11-05 MX MX2020004620A patent/MX2020004620A/es unknown
- 2018-11-06 AR ARP180103232A patent/AR113835A1/es unknown
- 2018-11-06 TW TW107139266A patent/TWI911137B/zh active
-
2020
- 2020-05-04 ZA ZA2020/02080A patent/ZA202002080B/en unknown
-
2023
- 2023-06-13 JP JP2023096692A patent/JP7752152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020118172A (ru) | 2021-12-08 |
| JP7296958B2 (ja) | 2023-06-23 |
| JP7752152B2 (ja) | 2025-10-09 |
| AU2018360744A1 (en) | 2020-05-07 |
| CN111629745A (zh) | 2020-09-04 |
| MX2020004620A (es) | 2020-10-12 |
| IL274098A (en) | 2020-06-30 |
| IL274098B1 (en) | 2024-08-01 |
| EP3706774A4 (en) | 2021-09-08 |
| EP3706774A1 (en) | 2020-09-16 |
| BR112020008936A2 (pt) | 2020-10-20 |
| ZA202002080B (en) | 2025-11-26 |
| CA3079523A1 (en) | 2019-05-09 |
| US11660328B2 (en) | 2023-05-30 |
| JP2021502389A (ja) | 2021-01-28 |
| WO2019090209A1 (en) | 2019-05-09 |
| IL274098B2 (en) | 2024-12-01 |
| KR20200085763A (ko) | 2020-07-15 |
| TW201922279A (zh) | 2019-06-16 |
| JP2023107883A (ja) | 2023-08-03 |
| US20210169986A1 (en) | 2021-06-10 |
| KR102825098B1 (ko) | 2025-06-26 |
| TWI911137B (zh) | 2026-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113835A1 (es) | Análogos y pepticuerpos de glp-2 para la administración antes, durante o después de la cirugía | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| JP2016519078A5 (https=) | ||
| BR112015021446A2 (pt) | métodos cirúrgicos empregando composições de peptídeo amfifílico purificado | |
| BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| CL2020001688A1 (es) | Vacunas liquidas de virus vivos envueltos. | |
| AR045906A1 (es) | Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2017007458A (es) | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. | |
| EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| MX390945B (es) | Compuestos para el tratamiento de tnbc. | |
| EP3773530A4 (en) | RAPID IMPROVEMENT OF VASCULAR DISEASES BY ADMINISTRATION OF VITAMIN K | |
| MX2015008529A (es) | Solucion para conservar conductos vasculares. | |
| MX2018012941A (es) | Formulaciones y metodos para tratar organismos fotosinteticos y mejorar las calidades y cantidades de los rendimientos con formulaciones de compuestos de glicano. | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| PE20140134A1 (es) | Metodos para mejorar la oxigenacion del tejido en peligro | |
| MX2023000398A (es) | Analogos de insulina novedosos y usos de estos. | |
| MX390948B (es) | Administracion intravenosa de citrulina durante cirugia. | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| EA201591910A1 (ru) | Стабильный раствор бромфенака | |
| BR112017006200A2 (pt) | dispositivos de fio de fita transósseo e um sistema e método para utilizar os dispositivos | |
| AR096514A1 (es) | Compuestos de ariltiazina como citoprotectores | |
| RU2013126506A (ru) | Способ лечения перелома межмыщелкового возвышения большеберцовой кости |